分化型甲状腺癌的碘-131治疗现状和进展

Postoperative treatment of differentiated thyroid carcinoma with radioiodine-131

作为分化型甲状腺癌(differentiated thyroid carcinoma,DTC)术后重要的靶向治疗手段,碘-131(^131I)治疗有效降低了部分中危DTC患者的潜在复发风险,以及存在摄碘病灶的高危DTC患者复发、死亡的风险。近年来,随着临床证据的增加,^131I治疗的目的、治疗前评估及风险分层系统、动态评估体系、甲状腺在DTC^131I诊治中的意义、分子病理特征及分子影像学在DTC诊治中的意义等方面取得了一定的进展,本文就上述问题加以综述。

Radioiodine-131(^131I)therapy as one of the post-surgical targeted therapies has been proven as an effective treatment modality in reducing the risk of recurrence and mortality in intermediate and high risk differentiated thyroid cancer (DTC).With increasing evidence over recent years,improvements in the management of DTC have been observed.In this review,several points and their influences on DTC decision making are discussed,including the purpose of ^131I therapy,evaluating system for risks and on-going response to therapy,as well as the significance of molecular features such as thyroglobulin,molecular pathology and nuclear medicine molecular imaging.